Feature | June 10, 2014

Opti-SPECT/PET/CT: Five Different Imaging Systems Now Combined

Wide range of molecular imaging modalities is at researchers’ fingertips with a hybrid device dedicated for early-stage clinical trials

June 10, 2014 – Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

The imaging device allows single photon emission tomography (SPECT), positron emission tomography (PET), X-ray computed tomography (CT), fluorescence and bioluminescence imaging — powerful imaging techniques that provide different information about anatomy and physiological processes happening within the body. With the Opti-SPECT/PET/CT system, SPECT or PET information details drug distribution and improves interpretation of optical data, while bioluminescence and fluorescence characterize additional tumor properties.  The tracers that are developed with the system will be used as a surgical guide for clinicians.

“We need to know as much as possible from our enemy: the tumor,” Frederik Beekman, Ph.D., explained.  Beekman is head of radiation technology and medical imaging and a professor at Delft University of Technology in Delft, The Netherlands. “This research proves that we can now obtain comprehensive data from five medical imaging systems in a single scan. It is minimally invasive and requires only a single dose of anesthesia.”

Opti-SPECT/PET/CT is built on a small scale for preclinical studies and allows scientists to use a gamut of imaging methods including high resolution nuclear medicine (SPECT and PET), radiological (CT) and optical imaging (fluorescence and bioluminescence). This means that information about organ function, structure and real-time physiological signals revealed within the light spectrum are all available in a synergistic fusion of advanced medical imaging. The hybrid system includes high-performance cameras and an on-board dark room. The molecular imaging platform could be used for new drug discovery, especially for imaging agents that could be used intraoperatively for patients undergoing cancer surgery.

To test the device, researchers imaged models and then mice in multiple studies using a fluorescent dye optical agent and a nuclear medicine imaging agent that combines a radioactive particle with a chemical drug compound. The agent is injected and then imaged as it homes in on and interacts with specific bodily functions. In this case, that function is angiogenesis, or the development of new blood vessels, which often proliferate as a tumor grows. Results of the study confirmed the imaging system’s functionality and proved that it was comparable to other add-on imaging platforms for preclinical studies.

For more information: www.snmmi.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | Computed Tomography (CT) | August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer
News | Lung Cancer | August 02, 2017
To raise public awareness of lung cancer—the leading cancer killer of men and women—the American Lung Association's...
GE’s DoseWatch is a digital informatics solution that automatically collects, monitors and reports on radiation dose indices for diagnostic imaging exams
News | Radiation Dose Management | July 31, 2017
GE Healthcare announced that it has licensed computed tomography (CT) organ dosimetry technology developed at Duke...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
New York Hospital Finds Significant Cost Savings With Toshiba’s Aquilion One CT
News | Computed Tomography (CT) | July 25, 2017
In five years, Kaleida Health’s Stroke Care Center (SCC) at the Gates Vascular Institute in Buffalo, N.Y., has realized...
Overlay Init